Human CXCL1/2/3/GRO Pan Specific Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB276
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Western Blot, Neutralization
Cited:
Immunohistochemistry-Paraffin, Western Blot, Neutralization, Antibody Array Development
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 31716
Product Specifications
Immunogen
E. coli-derived recombinant human CXCL2
Ala35-Asn107
Accession # P19875
Ala35-Asn107
Accession # P19875
Specificity
Detects human CXCL1/2/3 in direct ELISAs and Western blots.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human CXCL1/2/3/GRO Pan Specific Antibody
Chemotaxis Induced by CXCL2/GRO beta and Neutralization by Human CXCL1/2/3/GRO Antibody.
Recombinant Human CXCL2/GRO beta (Catalog # 176-GB) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR2 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CXCL2/GRO beta (6 ng/mL) is neutralized (green line) by increasing concentrations of Human CXCL1/2/3/GRO Monoclonal Antibody (Catalog # MAB276). The ND50 is typically 0.15-0.75 µg/mL.Detection of CXCL1/2/3/GRO Pan Specific by Western Blot
miR-182 upregulated NSCLC cells promote osteoclastogenesis through enhancing IL-8 secretion. A TRAP staining analysis of the osteoclast differentiation of RAW264.7 cells after cultured in the indicated CM for 6 days. Arrowheads indicate mature, multi-nucleated osteoclasts. B Transcriptome-seq combined with Gene Ontology analysis revealed the enrichment of multiple signaling pathways in miR-182-overexpressing A549 cells. C Volcano plot showing differentially expressed genes in miR-182-overexpressing A549 cells compared with the negative control cells, with selected cytokines highlighted. D qPCR analysis of the mRNA expression of IL-8, IL-1, IL-12 and CXCL3 in miR-182-overexpressing A549 (left) or H1299 cells relative to controls (right). E, F Western blotting of IL-8, IL-1, IL-12, and CXCL3 levels in CM from miR-182-overexpressing (left) or H1299 cells (right) relative to controls, with total protein staining (Coomassie) confirmed equal loading. F, G ELISA analysis of IL-8, IL-1, IL-12, and CXCL3 levels in the CM from miR-182-overexpressing (top) or H1299 cells (bottom) relative to controls (F) or in blood samples collected from mice bearing bone metastases developed by miR-182-overexpressing A549 cells or NC A549 cells (G). (H) TRAP staining analysis of the effects of depletion of indicated factors in the miR-182-CM (top) or their addition to the CM from A549 cells (bottom) on osteoclast differentiation of RAW264.7 cells. Arrowheads indicate mature, multi-nucleated osteoclasts. Scale bars, 50 μm. The average values ± SEM of three separate experiments are plotted. n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37127752), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of CXCL1/2/3/GRO Pan Specific by Western Blot
miR-182 upregulated NSCLC cells promote osteoclastogenesis through enhancing IL-8 secretion. A TRAP staining analysis of the osteoclast differentiation of RAW264.7 cells after cultured in the indicated CM for 6 days. Arrowheads indicate mature, multi-nucleated osteoclasts. B Transcriptome-seq combined with Gene Ontology analysis revealed the enrichment of multiple signaling pathways in miR-182-overexpressing A549 cells. C Volcano plot showing differentially expressed genes in miR-182-overexpressing A549 cells compared with the negative control cells, with selected cytokines highlighted. D qPCR analysis of the mRNA expression of IL-8, IL-1, IL-12 and CXCL3 in miR-182-overexpressing A549 (left) or H1299 cells relative to controls (right). E, F Western blotting of IL-8, IL-1, IL-12, and CXCL3 levels in CM from miR-182-overexpressing (left) or H1299 cells (right) relative to controls, with total protein staining (Coomassie) confirmed equal loading. F, G ELISA analysis of IL-8, IL-1, IL-12, and CXCL3 levels in the CM from miR-182-overexpressing (top) or H1299 cells (bottom) relative to controls (F) or in blood samples collected from mice bearing bone metastases developed by miR-182-overexpressing A549 cells or NC A549 cells (G). (H) TRAP staining analysis of the effects of depletion of indicated factors in the miR-182-CM (top) or their addition to the CM from A549 cells (bottom) on osteoclast differentiation of RAW264.7 cells. Arrowheads indicate mature, multi-nucleated osteoclasts. Scale bars, 50 μm. The average values ± SEM of three separate experiments are plotted. n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37127752), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human CXCL1/2/3/GRO Pan Specific Antibody
Application
Recommended Usage
Western Blot
1 µg/mL
Sample: Recombinant Human CXCL1/GRO alpha/KC/CINC-1 (Catalog # 275-GR)
Recombinant Human CXCL2/GRO beta/MIP-2/CINC-3 (Catalog # 276-GB)
Recombinant Human CXCL3/GRO gamma/CINC-2/DCIP-1 (Catalog # 277-GG)
Sample: Recombinant Human CXCL1/GRO alpha/KC/CINC-1 (Catalog # 275-GR)
Recombinant Human CXCL2/GRO beta/MIP-2/CINC-3 (Catalog # 276-GB)
Recombinant Human CXCL3/GRO gamma/CINC-2/DCIP-1 (Catalog # 277-GG)
Neutralization
Measured by its ability to neutralize CXCL1/2/3/GRO-induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CXCR2. The Neutralization Dose (ND50) is typically 0.5-2.5 µg/mL, 0.15-0.75µg/mL, and 0.1-0.5 µg/mL for Recombinant Human (rh) CXCL1, rhCXCL2, and rhCXCL3, respectively.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from ascites
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CXCL1/2/3/GRO
Alternate Names
FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1
UniProt
Additional CXCL1/2/3/GRO Products
Product Documents for Human CXCL1/2/3/GRO Pan Specific Antibody
Product Specific Notices for Human CXCL1/2/3/GRO Pan Specific Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...